Your browser doesn't support javascript.
loading
Association of adrenal steroids with metabolomic profiles in patients with primary and endocrine hypertension.
Knuchel, Robin; Erlic, Zoran; Gruber, Sven; Amar, Laurence; Larsen, Casper K; Gimenez-Roqueplo, Anne-Paule; Mulatero, Paolo; Tetti, Martina; Pecori, Alessio; Pamporaki, Christina; Langton, Katharina; Peitzsch, Mirko; Ceccato, Filippo; Prejbisz, Aleksander; Januszewicz, Andrzej; Adolf, Christian; Remde, Hanna; Lenzini, Livia; Dennedy, Michael; Deinum, Jaap; Jefferson, Emily; Blanchard, Anne; Zennaro, Maria-Christina; Eisenhofer, Graeme; Beuschlein, Felix.
Afiliação
  • Knuchel R; Klinik für Endokrinologie, Diabetologie und Klinische Ernährung, UniversitätsSpital Zürich (USZ) und Universität Zürich (UZH), Zurich, Switzerland.
  • Erlic Z; Klinik für Endokrinologie, Diabetologie und Klinische Ernährung, UniversitätsSpital Zürich (USZ) und Universität Zürich (UZH), Zurich, Switzerland.
  • Gruber S; Klinik für Endokrinologie, Diabetologie und Klinische Ernährung, UniversitätsSpital Zürich (USZ) und Universität Zürich (UZH), Zurich, Switzerland.
  • Amar L; Université Paris Cité, Paris Cardiovascular Research Center (PARCC), L'Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France.
  • Larsen CK; Département de Médecine Génomique des Tumeurs et des Cancers, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France.
  • Gimenez-Roqueplo AP; Centre de référence en maladies rares de la surrénale, Hôpital Européen Georges Pompidou, Paris, France.
  • Mulatero P; Université Paris Cité, Paris Cardiovascular Research Center (PARCC), L'Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France.
  • Tetti M; Université Paris Cité, Paris Cardiovascular Research Center (PARCC), L'Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France.
  • Pecori A; Département de Médecine Génomique des Tumeurs et des Cancers, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France.
  • Pamporaki C; Division of Internal Medicine and Hypertension Unit, Department of Medical Sciences, University of Torino, Torino, Italy.
  • Langton K; Division of Internal Medicine and Hypertension Unit, Department of Medical Sciences, University of Torino, Torino, Italy.
  • Peitzsch M; Division of Internal Medicine and Hypertension Unit, Department of Medical Sciences, University of Torino, Torino, Italy.
  • Ceccato F; Medical Clinic III, University Hospital Carl Gustav Carus, Technische Universität (TU) Dresden, Dresden, Germany.
  • Prejbisz A; Medical Clinic III, University Hospital Carl Gustav Carus, Technische Universität (TU) Dresden, Dresden, Germany.
  • Januszewicz A; Institute for Clinical Chemistry and Laboratory Medicine, University Hospital and Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
  • Adolf C; Unita' Operativa Complessa (UOC) Endocrinologia, Dipartimento di Medicina DIMED, Azienda Ospedaliera-Università di Padova, Padua, Italy.
  • Remde H; Department of Hypertension, National Institute of Cardiology, Warsaw, Poland.
  • Lenzini L; Department of Hypertension, National Institute of Cardiology, Warsaw, Poland.
  • Dennedy M; Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany.
  • Deinum J; Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of Würzburg, Würzburg, Germany.
  • Jefferson E; Internal & Emergency Medicine Unit, Department of Medicine - DIMED, University of Padua, Padua, Italy.
  • Blanchard A; The Discipline of Pharmacology and Therapeutics, School of Medicine, National University of Ireland, Galway, Ireland.
  • Zennaro MC; Department of Medicine, Section of Vascular Medicine, Radboud University Medical Center, Nijmegen, Netherlands.
  • Eisenhofer G; Division of Population Health and Genomics, School of Medicine, University of Dundee, Dundee, United Kingdom.
  • Beuschlein F; Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Centre d'Investigations Cliniques, Paris, France.
Front Endocrinol (Lausanne) ; 15: 1370525, 2024.
Article em En | MEDLINE | ID: mdl-38596218
ABSTRACT

Introduction:

Endocrine hypertension (EHT) due to pheochromocytoma/paraganglioma (PPGL), Cushing's syndrome (CS), or primary aldosteronism (PA) is linked to a variety of metabolic alterations and comorbidities. Accordingly, patients with EHT and primary hypertension (PHT) are characterized by distinct metabolic profiles. However, it remains unclear whether the metabolomic differences relate solely to the disease-defining hormonal parameters. Therefore, our objective was to study the association of disease defining hormonal excess and concomitant adrenal steroids with metabolomic alterations in patients with EHT.

Methods:

Retrospective European multicenter study of 263 patients (mean age 49 years, 50% females; 58 PHT, 69 PPGL, 37 CS, 99 PA) in whom targeted metabolomic and adrenal steroid profiling was available. The association of 13 adrenal steroids with differences in 79 metabolites between PPGL, CS, PA and PHT was examined after correction for age, sex, BMI, and presence of diabetes mellitus.

Results:

After adjustment for BMI and diabetes mellitus significant association between adrenal steroids and metabolites - 18 in PPGL, 15 in CS, and 23 in PA - were revealed. In PPGL, the majority of metabolite associations were linked to catecholamine excess, whereas in PA, only one metabolite was associated with aldosterone. In contrast, cortisone (16 metabolites), cortisol (6 metabolites), and DHEA (8 metabolites) had the highest number of associated metabolites in PA. In CS, 18-hydroxycortisol significantly influenced 5 metabolites, cortisol affected 4, and cortisone, 11-deoxycortisol, and DHEA each were linked to 3 metabolites. Discussions Our study indicates cortisol, cortisone, and catecholamine excess are significantly associated with metabolomic variances in EHT versus PHT patients. Notably, catecholamine excess is key to PPGL's metabolomic changes, whereas in PA, other non-defining adrenal steroids mainly account for metabolomic differences. In CS, cortisol, alongside other non-defining adrenal hormones, contributes to these differences, suggesting that metabolic disorders and cardiovascular morbidity in these conditions could also be affected by various adrenal steroids.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Paraganglioma / Feocromocitoma / Cortisona / Neoplasias das Glândulas Suprarrenais / Síndrome de Cushing / Diabetes Mellitus / Hipertensão Limite: Female / Humans / Male / Middle aged Idioma: En Revista: Front Endocrinol (Lausanne) Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Paraganglioma / Feocromocitoma / Cortisona / Neoplasias das Glândulas Suprarrenais / Síndrome de Cushing / Diabetes Mellitus / Hipertensão Limite: Female / Humans / Male / Middle aged Idioma: En Revista: Front Endocrinol (Lausanne) Ano de publicação: 2024 Tipo de documento: Article